Sandoz

Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
Amgen
Enbrel
patents
Erelzi
Flag link:
Enbrel ruling lifts Amgen shares
Enbrel ruling lifts Amgen shares
BioCentury
Amgen
Enbrel
patents
Sandoz
generics
Flag link:
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
Flag link:
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Fierce Pharma
Novartis
generics
Sandoz
Flag link:
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Fierce Pharma
Novartis
Mylan
Pfizer
EpiPens
Sandoz
Symjepi
drug launches
Adamis Pharmaceuticals
Flag link:
Sandoz launches oncology generic gefitinib in 13 EU countries
Sandoz launches oncology generic gefitinib in 13 EU countries
Pharmaceutical Business Review
Sandoz
Novartis
generics
gefitinib
metastatic non-small cell lung cancer
Flag link:
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlement
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlement
Fierce Pharma
Sanofi
bloodthinners
Lovenox
generics
Amphastar
Momenta
Sandoz
Flag link:
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Endpoints
Novartis
R&D
Sandoz
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Fierce Pharma
digital pharma
Sandoz
Novartis
Flag link:
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Yahoo/Reuters
Novartis
Sandoz
generics
price fixing
Flag link:
Novartis Poaches GSK Veteran as New Sandoz CEO
Novartis Poaches GSK Veteran as New Sandoz CEO
BioSpace
Novartis
Sandoz
generics
Pharma CEOs
Richard Saynor
GSK
Flag link:
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
BioSpace
United Therapeutics
PAH
Remodulin
generics
Sandoz
Flag link:
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Biopharma Dive
FDA
Novartis
biosimilars
Sandoz
Amgen
Neulasta
Flag link:
CEO of Novartis’ generics unit quits, sparking sale speculation
CEO of Novartis’ generics unit quits, sparking sale speculation
Pharmaforum
Novartis
Sandoz
generics
M&A
Richard Francis
biosimilars
Flag link:
Indivior introduces generic version of Suboxone opioid drug in US
Indivior introduces generic version of Suboxone opioid drug in US
Pharmaceutical Business Review
Indivior
Sandoz
generics
opioids
Suboxone Film
Flag link:
‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
Fierce Pharma
Novartis
Sandoz
layoffs
drug manufacturing
Flag link:
Novartis plots new course for Sandoz
Novartis plots new course for Sandoz
BioCentury
Novartis
Sandoz
generics
Flag link:
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
Fierce Pharma
UnitedHealthcare
generics
price fixing
drug pricing
Mylan
Teva Pharmaceuticals
Sandoz
Actavis
Par Pharmaceutical
Sun Pharma
Aurobindo
Taro Pharmaceuticals
Flag link:
Sandoz launches EpiPen rival at $250 per two-pack
Sandoz launches EpiPen rival at $250 per two-pack
BioPharma Dive
Sandoz
Novartis
EpiPens
Symjepi
Flag link:
Adamis stock surges on release of EpiPen alternative
Adamis stock surges on release of EpiPen alternative
Marketwatch
Adamis
Mylan
Sandoz
EpiPens
Symjepi
Flag link:

Pages